Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease

Author(s)

Lara, Leonardo da Silva ^[1] ; Andrade-Lima, Leonardo ^[2] ; Calvet, Claudia Magalhaes ^[1] ; Borsoi, Juliana ^[2] ; Alberto Duque, Thabata Lopes ^[3] ; Henriques-Pons, Andrea ^[4] ; Souza Pereira, Mirian Claudia ^[1] ; Pereira, Lygia Veiga ^[2]

Affiliation

^[1] Fiocruz MS, Inst Oswaldo Cruz, Lab Ultraestrutura Celular, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil

^[2] Univ Sao Paulo, Inst Biosci, Natl Lab Embryon Stem Cells LaNCE, BR-05508090 Sao Paulo, SP - Brazil

^[3] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Celular, Manguinho, RJ - Brazil

^[4] Fiocruz MS, Inst Oswaldo Cruz, Lab Inovacoes Terapias Ensino & Bioprod, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil

• Document type: Journal article
• Source: Microbes and Infection; v. 20, n. 5, p. 312-316, MAY 2018.
• Web of Science Citations: 1

Abstract

Chagas disease, caused by Trypanosoma cruzi, is an important global public health problem which, despite partial efficacy of benznidazole (Bz) in acute phase, urgently needs an effective treatment. Cardiotoxicity is a major safety concern for conduction of more accurate preclinical drug screening platforms. Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM) are a reliable model to study genetic and infectious cardiac alterations and may improve drug development. Herein, we introduce hiPSC-CM as a suitable model to study T. cruzi heart infection and to predict the safety and efficacy of anti-T. cruzi drugs. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. (AU)

• FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC